Five Prime Therapeutics, Inc. clinical trials
Acquired by Amgen, Apr 16, 2021 · source ↗
The registry lists 11 studies whose lead sponsor is Five Prime Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 23, 2025.
Before and after it joined Amgen
- First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- 11
- First submitted after Five Prime Therapeutics, Inc. became part of Amgen
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Five Prime Therapeutics, Inc.11 studies
Something wrong with this grouping? Tell us on the Amgen page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Amgen studies →
- FPT155 in Patients With Advanced Solid TumorsTerminatedNCT04074759Phase 1
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- FPA150 in Patients With Advanced Solid TumorsTerminatedNCT03514121Early Phase 1
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid TumorsCompletedNCT02318329Phase 1
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal CancerCompletedNCT03343301Phase 1
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Phase 2
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersCompletedNCT02526017Phase 1
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- Study of FP-1039 in Subjects With Endometrial CancersWithdrawnNCT01244438Phase 2
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis SubjectsTerminatedNCT01962337Phase 1
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder CancerNo longer availableNCT03801278
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- Safety Study of FP-1039 To Treat CancerCompletedNCT00687505Phase 1
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen
- Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell TumorCompletedNCT02471716Phase 1/2
Sponsor listed in the registry: Five Prime Therapeutics, Inc. · First submitted before Five Prime Therapeutics, Inc. became part of Amgen